| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 190 | 0 | - | - |
| Research and development | 22,130 | 15,384 | 11,814 | 14,807 |
| General and administrative | 4,805 | 4,929 | 3,959 | 3,336 |
| Total operating expenses | 26,935 | 20,313 | 15,773 | 18,143 |
| Loss from operations | -26,745 | -20,313 | -15,773 | -18,143 |
| Total other income (expense), net | 999 | 781 | 892 | 882 |
| Consolidated net loss | -25,746 | -19,532 | -14,881 | -17,261 |
| Net loss (gain) attributable to noncontrolling interest in pangu biopharma limited | -2 | -1 | -1 | -2 |
| Net loss attributable to atyr pharma, inc | -25,744 | -19,531 | -14,880 | -17,259 |
| Earnings per share, basic | -0.26 | -0.22 | -0.17 | -0.23 |
| Net loss per share - diluted | -0.26 | -0.22 | -0.17 | -0.23 |
| Weighted average number of shares outstanding, basic | 97,153,541 | 90,120,235 | 86,485,126 | 75,801,666 |
| Weighted average number of shares outstanding, diluted | 97,153,541 | 90,120,235 | 86,485,126 | 75,801,666 |
aTYR PHARMA INC (ATYR)
aTYR PHARMA INC (ATYR)